董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Alan W. Dunton | 男 | Director | 70 | 未披露 | 未持股 | 2024-06-27 |
| J. Stanley Hull | 男 | Director | 71 | 未披露 | 未持股 | 2024-06-27 |
高管介绍
暂无数据
董事简历
中英对照 | 中文 | 英文- Alan W. Dunton
-
Alan W. Dunton，自2019年3月起担任CorMedix的董事。他是Danerius，LLC的创始人和首席顾问，该公司是他于2006年开始的生物技术和制药咨询业务。从1994年起，他在强生制药部门担任研发高级职务，包括在强生制药部门的主要研究、开发和监管部门杨森公司担任总裁兼董事总经理。从2007年1月到2009年3月，Dunton博士担任Panacos Pharmaceuticals，Inc.的总裁兼首席执行官。从2015年11月到2018年3月，Dunton博士担任私营制药公司Purdue Pharma L.P.的研究、开发和监管事务主管/高级副总裁。除了CorMedix，Dunton博士目前还在三家上市公司的董事会任职。作为PALATIN技术和Oragenics公司的董事，他主持了两家公司的薪酬委员会。他还担任这些公司的审计委员会成员。此外，Dunton博士还是Recce Pharma Ltd.的董事会成员，该公司是一家澳大利亚公共生物技术公司，专注于为严重和危及生命的疾病开发新型抗感染药物。Dunton博士以优异成绩获得纽约州立大学布法罗分校的生物化学理学学士学位，并获得纽约大学医学院的医学博士学位。
Alan W. Dunton,has served as a Director of Oragenics, Inc. since April 2011. He is the principal owner of Danerius, LLC, a biotechnology consulting company which he founded in 2006. In addition to Oragenics, he is currently a Director of the public biotechnology company, Palatin, Inc. (AMEX: PTN), CorMedix (NASDAQ: CRMD) and Recce Pharmaceuticals (ASX: RCE). Dr. Dunton has held significant senior positions in major pharmaceutical companies. Most recent was from November 2015 through March 2018 as the Senior Vice President of Research, Development and Regulatory Affairs of Purdue Pharma L.P., a private pharmaceutical company. From January 2007 until March 2009, Dr. Dunton served as President and Chief Executive Officer of Panacos Pharmaceuticals, Inc. In 2005, Dr. Dunton served as the Non-Executive Chairman of the Board of Directors of ActivBiotics, Inc., a private biopharmaceutical company. Previously, he was the President and Chief Executive Officer of Metaphore Pharmaceuticals, Inc. from 2003 until 2006, when it merged with ActivBiotics. From 2004 until 2005, Dr. Dunton served as a member of the Board of Directors of Vicuron Pharmaceuticals until it was acquired by Pfizer, Inc. In 2002, Dr. Dunton served as President, Chief Operating Officer and a Director of Emisphere Technologies, Inc., a biopharmaceutical company. From 1994 to 2001, Dr. Dunton was a senior executive in various capacities in the Pharmaceuticals Group of Johnson & Johnson. From 1999 to 2001, Dr. Dunton was President and Managing Director of The Janssen Research Foundation, a Johnson & Johnson company. From 1998 to 1999, he served as Group Vice President of Global Clinical Research and Development of Janssen. Prior to joining Janssen, Dr. Dunton was Vice President of Global Clinical Research and Development at the R.W. Johnson Pharmaceutical Research Institute, also a Johnson & Johnson company. Prior to joining Johnson & Johnson, Dr. Dunton held positions in clinical research and development at Syntex Corporation, CIBA-GEIGY Corporation and Hoffmann La Roche Inc. Dr. Dunton holds a MD degree from New York University School of Medicine, where he completed his residency in internal medicine. He also was a Fellow in Clinical Pharmacology at the New York Hospital/Cornell University Medical Center. - Alan W. Dunton，自2019年3月起担任CorMedix的董事。他是Danerius，LLC的创始人和首席顾问，该公司是他于2006年开始的生物技术和制药咨询业务。从1994年起，他在强生制药部门担任研发高级职务，包括在强生制药部门的主要研究、开发和监管部门杨森公司担任总裁兼董事总经理。从2007年1月到2009年3月，Dunton博士担任Panacos Pharmaceuticals，Inc.的总裁兼首席执行官。从2015年11月到2018年3月，Dunton博士担任私营制药公司Purdue Pharma L.P.的研究、开发和监管事务主管/高级副总裁。除了CorMedix，Dunton博士目前还在三家上市公司的董事会任职。作为PALATIN技术和Oragenics公司的董事，他主持了两家公司的薪酬委员会。他还担任这些公司的审计委员会成员。此外，Dunton博士还是Recce Pharma Ltd.的董事会成员，该公司是一家澳大利亚公共生物技术公司，专注于为严重和危及生命的疾病开发新型抗感染药物。Dunton博士以优异成绩获得纽约州立大学布法罗分校的生物化学理学学士学位，并获得纽约大学医学院的医学博士学位。
- Alan W. Dunton,has served as a Director of Oragenics, Inc. since April 2011. He is the principal owner of Danerius, LLC, a biotechnology consulting company which he founded in 2006. In addition to Oragenics, he is currently a Director of the public biotechnology company, Palatin, Inc. (AMEX: PTN), CorMedix (NASDAQ: CRMD) and Recce Pharmaceuticals (ASX: RCE). Dr. Dunton has held significant senior positions in major pharmaceutical companies. Most recent was from November 2015 through March 2018 as the Senior Vice President of Research, Development and Regulatory Affairs of Purdue Pharma L.P., a private pharmaceutical company. From January 2007 until March 2009, Dr. Dunton served as President and Chief Executive Officer of Panacos Pharmaceuticals, Inc. In 2005, Dr. Dunton served as the Non-Executive Chairman of the Board of Directors of ActivBiotics, Inc., a private biopharmaceutical company. Previously, he was the President and Chief Executive Officer of Metaphore Pharmaceuticals, Inc. from 2003 until 2006, when it merged with ActivBiotics. From 2004 until 2005, Dr. Dunton served as a member of the Board of Directors of Vicuron Pharmaceuticals until it was acquired by Pfizer, Inc. In 2002, Dr. Dunton served as President, Chief Operating Officer and a Director of Emisphere Technologies, Inc., a biopharmaceutical company. From 1994 to 2001, Dr. Dunton was a senior executive in various capacities in the Pharmaceuticals Group of Johnson & Johnson. From 1999 to 2001, Dr. Dunton was President and Managing Director of The Janssen Research Foundation, a Johnson & Johnson company. From 1998 to 1999, he served as Group Vice President of Global Clinical Research and Development of Janssen. Prior to joining Janssen, Dr. Dunton was Vice President of Global Clinical Research and Development at the R.W. Johnson Pharmaceutical Research Institute, also a Johnson & Johnson company. Prior to joining Johnson & Johnson, Dr. Dunton held positions in clinical research and development at Syntex Corporation, CIBA-GEIGY Corporation and Hoffmann La Roche Inc. Dr. Dunton holds a MD degree from New York University School of Medicine, where he completed his residency in internal medicine. He also was a Fellow in Clinical Pharmacology at the New York Hospital/Cornell University Medical Center.
- J. Stanley Hull
-
J. Stanley Hull，2005年9月起担任董事。他在销售和营销方面，有着30多年的经验。他在1987年10月加入Glaxo Smith Kline，这是一个研究型制药公司；于2010年5月退休，时任药物高级副总裁；此前，曾在Glaxo Smith Kline的研发机构工作，担任过副总裁、神经病与精神病疗法开发及产品策略全球总监。此前，他是Glaxo Wellcome感染性疾病和肠胃病部门的营销副总裁。他在1978年进入制药行业，任职于SmithKline and French Laboratories。他获得了North Carolina大学at Greensboro的工商管理学士学位。
J. Stanley Hull,has been a director of Palatin since September 2005. Mr. Hull has over three decades of experience in the field of sales, marketing, and drug development. Mr. Hull joined GlaxoSmithKline, a research-based pharmaceutical company, in October 1987 and retired as Senior Vice President, Pharmaceuticals – North America in May 2010. Mr. Hull was responsible for all commercial activities including sales, marketing, sales training, and office operations. Previously, Mr. Hull served in the R&D organization of Glaxo Wellcome as Vice President and Worldwide Director of Therapeutic Development and Product Strategy – Neurology and Psychiatry. Prior to his service in the R&D organization he was Vice President of Marketing – Infectious Diseases and Gastroenterology for Glaxo Wellcome-U.S. Mr. Hull started his career in the pharmaceutical industry with SmithKline and French Laboratories in 1978. Mr. Hull received his B.S. in business administration from the University of North Carolina at Greensboro. - J. Stanley Hull，2005年9月起担任董事。他在销售和营销方面，有着30多年的经验。他在1987年10月加入Glaxo Smith Kline，这是一个研究型制药公司；于2010年5月退休，时任药物高级副总裁；此前，曾在Glaxo Smith Kline的研发机构工作，担任过副总裁、神经病与精神病疗法开发及产品策略全球总监。此前，他是Glaxo Wellcome感染性疾病和肠胃病部门的营销副总裁。他在1978年进入制药行业，任职于SmithKline and French Laboratories。他获得了North Carolina大学at Greensboro的工商管理学士学位。
- J. Stanley Hull,has been a director of Palatin since September 2005. Mr. Hull has over three decades of experience in the field of sales, marketing, and drug development. Mr. Hull joined GlaxoSmithKline, a research-based pharmaceutical company, in October 1987 and retired as Senior Vice President, Pharmaceuticals – North America in May 2010. Mr. Hull was responsible for all commercial activities including sales, marketing, sales training, and office operations. Previously, Mr. Hull served in the R&D organization of Glaxo Wellcome as Vice President and Worldwide Director of Therapeutic Development and Product Strategy – Neurology and Psychiatry. Prior to his service in the R&D organization he was Vice President of Marketing – Infectious Diseases and Gastroenterology for Glaxo Wellcome-U.S. Mr. Hull started his career in the pharmaceutical industry with SmithKline and French Laboratories in 1978. Mr. Hull received his B.S. in business administration from the University of North Carolina at Greensboro.